Mixlab
New York, US · Founded 2017 · Delaware corporation · 5 known investors
Mixlab is a veterinary pharmacy providing compounded, commercial, and over-the-counter medications for animals across all 50 states. The company serves pet owners, veterinarians, and caregivers of equine and specialty animals through direct-to-consumer delivery and an AI-powered platform for veterinarians.
Also known as Mixlab, Inc.
Founders & leadership
Board
Investors · 5
Also in the syndicate · 1
Reported raises · per SEC filings
Form D private placements$10.6M disclosed across 2 of 4 rounds · 2019–2023
▶$2MraisedAug 2020 · 7 investors · Other Health CareRule 506(b)
- Frederic DijolsExecutive Officer, Director
- Edward KimDirector
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$8.6MraisedMay 2019 · 37 investors · Other Health CareRule 506(b)
- Frederic Pierre DijolsExecutive Officer, Director
- Edward KimDirector
- Offering amount
- $8.6M
- Amount sold
- $8.6M
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Mixlab is a full-service veterinary pharmacy that dispenses compounded, commercial and over-the-counter medications for animals and ships them to customers in all 50 states. The company compounds prescriptions to order, tailoring dosage, dosage form and flavor to an individual animal, and offers more than 30 flavor options backed by a flavor guarantee. It serves dogs, cats, equine, wildlife and other specialty animals, with product categories spanning flea and tick, heartworm prevention, arthritis and joint health, anxiety, gastrointestinal, cardiac, seizure, respiratory, allergy, urinary and kidney, diabetes and sedation.
For pet owners, orders are placed online, with Mixlab coordinating prescription approval directly with the animal's veterinarian, shipping free of charge, and providing order tracking through an owner portal plus refill reminders and text-based updates; shipments arrive in personalized packaging. For veterinary prescribers, Mixlab operates eMix, an online platform for submitting prescriptions, approving refills, tracking orders and accessing patient history, with integrations and API access; eMix is powered by Maisy, the company's AI engine, which supports workflow automation and recommendations. Mixlab describes itself as veterinary-exclusive and states its pharmacies are PCAB-accredited.
Founding story
Mixlab was founded in 2017 by Fred Dijols together with CXO Stella Kim and Director of Pharmacy Vinnie Dam, with the aim of making medicating pets easier by addressing flavor, form and dosage difficulties. Dijols holds an M.S. from Stanford and an MBA from Harvard Business School; Kim holds a degree from NYU with prior experience at firms including IBM, and Dam holds a USC degree with pharmaceutical experience.
Business model
Mixlab operates its own compounding and dispensing pharmacies and sells prescription and over-the-counter animal medications directly to pet owners on the basis of veterinarian prescriptions, while providing veterinarians with a free-to-use prescribing and fulfillment platform. The company handles fulfillment, delivery and refill management on behalf of prescribing practices.
Revenue is generated from the sale and fulfillment of compounded, branded, generic and over-the-counter animal medications ordered by pet owners and prescribed by veterinarians.
Traction
As of the August 2023 funding announcement, Mixlab served thousands of pet parents and veterinarians nationwide from labs in New York City and Los Angeles, with an investor citing customer service and retention metrics as a factor in the round. The company reported a year of rapid growth ahead of its January 2026 Maisy announcement. Veterinarians at practices including ACCESS Specialty Animal Hospitals, Bond Veterinary Clinic and The Vets provide public testimonials.
Latest developments
In January 2026 Mixlab announced the upcoming launch of Maisy, an AI health partner and the engine behind its eMix prescribing platform. Earlier, in September 2024, it introduced a client portal to simplify veterinary prescription management.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
The company positions itself as a modern, full-service veterinary pharmacy operating in the animal health segment of the pet care industry, which its 2023 announcement cited as a $235B global market in 2022 projected to reach $368B by 2030. Initially focused primarily on compounded medications, Mixlab has broadened into branded, generic and over-the-counter products to serve as a single source for pet health and wellness needs.
Mixlab differentiates on customization of medications (dosage, form and more than 30 flavors with a flavor guarantee), veterinary-exclusive focus with PCAB-accredited pharmacies, free next-day delivery nationwide and same-day delivery in metro areas near its labs, proprietary prescribing technology that replaces phone and fax workflows, and a service model emphasizing proactive text communication and personalized packaging.
Technology
The company's proprietary technology includes eMix, an online, AI-powered prescribing platform for veterinarians covering catalog browsing, prescription submission, refill management and real-time order tracking, with compliance workflows, system integrations and API access. eMix is powered by Maisy, Mixlab's AI engine, announced as an AI health partner in January 2026. A client/owner portal introduced in September 2024 supports order tracking and prescription management.
Go-to-market
Mixlab reaches pet owners directly through its e-commerce site and reaches veterinarians through its eMix prescribing platform, account requests and product demos, positioning itself as a pharmacy partner and extension of the veterinary practice. It also invests in customer experience touches such as personalized packaging, text-based communication and follow-up messages, and has hired dedicated sales and marketing leadership.
Pet owners, veterinarians and veterinary practices, and caregivers of equine, wildlife and other specialty animals.
Geography
Headquartered in New York City, with early offices on West 37th Street. Mixlab ships to all 50 states and, as of August 2023, operated pharmacy labs in New York City, Los Angeles and Florida, enabling same-day delivery in those metro areas including Miami-West Palm Beach.
History
The founding team began compounding pet medications in 2017 from a New York City base. Mixlab raised $8.5 million in seed funding from international investors, using the proceeds to grow in the Northeast, obtain additional licenses and roll out labs nationwide. In 2022 it appointed George Koveos (previously COO of Ro) as Chief Operating Officer and Libby Loskota (previously global marketing lead at TaskUs) as SVP of Sales and Marketing. In August 2023 it announced a $10M round led by Vanterra Ventures and opened a third pharmacy in Florida. It launched a client portal in September 2024 and announced the Maisy AI health partner in January 2026.
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 4
by search overlapCompanies competing with Mixlab for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 6
launches, deals, and filingsMixlab announced the upcoming launch of Maisy, its AI health partner, following what the company described as a year of rapid growth.
Mixlab announced a new client portal intended to simplify veterinary prescription management.
Following the funding, Mixlab expanded from its New York City and Los Angeles labs with a third pharmacy in Florida, offering same-day delivery in the Miami-West Palm Beach area.
Mixlab announced a $10M funding round led by Vanterra Ventures with participation from Lakehouse Ventures and others, earmarked for expanding operations and product offering, enhancing its technology platform and reaching profitability. Ellis Fried, VP of Vanterra Ventures, joined the board of directors.
$10M source ↗
Mixlab appointed George Koveos, previously COO of Ro, as Chief Operating Officer, and Libby Loskota, previously head of global marketing at TaskUs, as SVP of Sales and Marketing.
Mixlab raised $8.5 million in seed funding from international investors, to be used for growth in the Northeast, obtaining additional pharmacy licenses, rolling out labs nationwide and expanding its New York City team.
$8.5M source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structure▸Research sources · 7
primary sources listed
- Mixlabmixlabrx.com · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Mixlab do?
- Mixlab is a US veterinary pharmacy delivering compounded, commercial and OTC pet medications with an online prescribing platform.
- Who are Mixlab's investors?
- Mixlab's investors include Eastward Capital Partners, Partners Resolute, R/GA Ventures, Tq Ventures Llc.
- How much funding has Mixlab raised?
- Mixlab has disclosed $10.6M raised across 2 of its 4 known rounds.
- Where is Mixlab headquartered?
- Mixlab is headquartered in New York, US.
